Swedish Orphan Biovitrum

Deutsche Bank upgrades Sobi’s target price to 515 kr, citing robust Q2 earnings, the Altuvoct engine, and promising orphan drug Tryngolza ahead of its 2029 patent cliff.

Explore how Swedish Orphan Biovitrum’s strong Q4 results, Altuvoct & Doptelet performance, and analyst‑raised target prices signal robust growth—while patent cliffs & market saturation shape future strategy.

NASP, Sobi’s nano‑encapsulated sirolimus‑pegadricase combo, cuts gout uric acid by 2.5 mg/dL with no safety hits—yet FDA demands tighter CMC and CMF controls before approval.

Swedish Orphan Biovitrum (Sobi) tops Q1 expectations with double‑digit haemophilia and immunology growth, strong EBITDA, and a solid pipeline for future earnings momentum.

Nordea boosts Sobi’s target price, citing a $300‑$400 M rare‑disease pipeline and new board confidence, while Ionis cuts prices to support shared access and growth.

Swedish Orphan Biovitrum’s Aspaveli gains EU approval, boosting sales guidance and brokerage upside as the company expands its rare‑kidney drug portfolio.